and the Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A - Bray, GL; Gomperts, ED; Courter, S; Gruppo, R; Gordon, EM; Manco-John-son, M; Shapiro, A; Scheibel, E; White, G, III; Lee, M (Blood, 1994)